Access cutting-edge solid tumors treatment through this clinical trial at a research site in Atlanta. Study-provided care at no cost to qualified participants.
Access solid tumors specialists in Atlanta at no cost
This study follows strict safety protocols and ethical guidelines
All study-related solid tumors treatment provided free
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.
Sponsor: Inhibrx Biosciences, Inc
Check if you qualify for this solid tumors clinical trial in Atlanta, GA
If you're searching for solid tumors treatment options in Atlanta, GA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Atlanta research site is actively enrolling participants for this clinical trial. You'll receive care from experienced solid tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.